Advances in Ebolavirus
Zaire ebolavirus, more commonly known as simply Ebola virus (/i?bo?l?/, /??bo?l?/) (EBOV), is one of six known species within the genus Ebolavirus. Four of the six known ebolaviruses, including EBOV, cause a severe and often fatal hemorrhagic fever in humans and other mammals, known as Ebola virus disease (EVD). Ebola virus has caused the majority of human deaths from EVD and is the cause of the 2013–2016 Ebola virus epidemic in West Africa, which resulted in at least 28,646 suspected cases and 11,323 confirmed deaths.
Ebola virus and its genus were both originally named for Zaire (now the Democratic Republic of Congo), the country where it was first described, and was at first suspected to be a new "strain" of the closely related Marburg virus.[5][6] The virus was renamed "Ebola virus" in 2010 to avoid confusion. Ebola virus is the single member of the species Zaire ebolavirus, which is the type species for the genus Ebolavirus, family Filoviridae, order Mononegavirales. The members of the species are called Zaire ebolaviruses. The natural reservoir of Ebola virus is believed to be bats, particularly fruit bats, and it is primarily transmitted between humans and from animals to humans through body fluids.
Components of the Book:
  • Chapter 1
    Ebolavirus diagnosis made simple, comparable and faster than molecular detection methods: preparing for the future
  • Chapter 2
    2.Expression of microRNA in human retinal pigment epithelial cells following infection with Zaire ebolavirus
  • Chapter 3
    Mapping HLA-A2, -A3 and -B7 supertype-restricted T-cell epitopes in the ebolavirus proteome
  • Chapter 4
    TIM-1 acts a dual-attachment receptor for Ebolavirus by interacting directly with viral GP and the PS on the viral envelope
  • Chapter 5
    The face of Ebola: changing frequency of haemorrhage in the West African compared with Eastern-Central African outbreaks
  • Chapter 6
    How severe and prevalent are Ebola and Marburg viruses? A systematic review and meta-analysis of the case fatality rates and seroprevalence
  • Chapter 7
    Understanding Ebola: the 2014 epidemic
  • Chapter 8
    High prevalence of IgG antibodies to Ebola virus in the Efé pygmy population in the Watsa region, Democratic Republic of the Congo
  • Chapter 9
    Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus
  • Chapter 10
    10.Investigating Ebola virus pathogenicity using molecular dynamics
  • Chapter 11
    Ebola Virus Infection: Overview and Update on Prevention and Treatment
  • Chapter 12
    Flexible docking-based molecular dynamics simulation of natural product compounds and Ebola virus Nucleocapsid (EBOV NP): a computational approach to discover new drug for combating Ebola
Readership: Students, academics, teachers and other people attending or interested in Ebolavirus
Shawn Todd, CSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Australia

Joanne Macdonald, Division of Experimental Therapeutics, Department of Medicine, Columbia University, New York, USA

Asif M. Khan, Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, USA

Shuai Yuan, University of Chinese Academy of Sciences, Beijing, China

Jolie Kaner, Department of Epidemiology, Oregon Health and Science University, Portland, USA

Matthias Borchert, Institute of Tropical Medicine and International Health, Charité – Universitätsmedizin Berlin, Berlin, Germany

and more...
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top